New Delhi: India has achieved a significant breakthrough in animal healthcare with the development of its first indigenous vaccine against H5N1 bird flu, marking an important step towards strengthening the country’s preparedness against highly pathogenic avian influenza and protecting its poultry industry.
Union Agriculture and Farmers’ Welfare Minister Shivraj Singh Chouhan on Friday dedicated the vaccine to the nation at a programme organised at the Indian Council of Agricultural Research–National Institute of High Security Animal Diseases (ICAR-NIHSAD) in Bhopal, Madhya Pradesh.
Developed entirely by scientists at ICAR-NIHSAD, the inactivated vaccine specifically targets the H5N1 virus belonging to Clade 2.3.2.1a, a strain responsible for a significant proportion of bird flu outbreaks among chickens in India.
The development is being viewed as a major achievement in India’s animal disease research and a boost to the government’s drive towards self-reliance in vaccine technology.
Shri Shivraj Singh Chouhan, Union Agriculture Minister, announced that India’s first indigenous H5N1 vaccine will be dedicated to the nation on 20 November— a major step towards poultry safety and Atmanirbhar Bharat.
#ICAR @ChouhanShivraj @PIB_India @AgriGoI https://t.co/DrtHnP5CLP— Indian Council of Agricultural Research. (@icarindia) November 19, 2026
Affordable Vaccine to Protect Poultry Farmers
The new vaccine is expected to strengthen disease prevention in the poultry sector, where bird flu outbreaks frequently result in substantial financial losses through mass culling, restrictions on poultry trade and disruptions in the supply chain.
According to reports, the vaccine is expected to cost approximately ₹1–2 per dose, potentially making it an affordable disease-control option for poultry farmers.
Chouhan described the development as an example of India’s growing scientific capabilities and said the vaccine would play an important role in protecting poultry populations and safeguarding farmers’ livelihoods.
He also congratulated the scientists and researchers involved in developing the vaccine, acknowledging their contribution to strengthening India’s animal healthcare infrastructure.
More Than 500 Bird Flu Outbreaks Reported Since 2006
The development assumes significance given India’s long-standing battle against avian influenza.
According to the Agriculture Ministry, more than 500 combined outbreaks of H5N1 and H5N8 have been reported in the country since bird flu was first detected in India in 2006.
Highly Pathogenic Avian Influenza (HPAI), commonly known as bird flu, is a serious viral disease affecting poultry and other bird species. In severe outbreaks, mortality among infected birds can approach 100 per cent.
The consequences extend beyond poultry farms. Governments often have to undertake large-scale culling, impose movement restrictions and introduce trade controls to contain the infection. These measures can severely affect poultry farmers, businesses and the wider agricultural economy.
The 2006 outbreak alone caused estimated direct and indirect economic losses of ₹2,200–3,000 crore, according to the Agriculture Ministry.
Why the H5N1 Vaccine Matters
The vaccine is particularly important because, until now, no specific commercial vaccine was available against the H5N1 Clade 2.3.2.1a strain circulating in India.
The virus has also been detected in different animal species, including mammals, raising concerns about its potential spread beyond poultry populations.
The World Health Organization has repeatedly highlighted the public health risks associated with avian influenza. Although human infections remain relatively uncommon, certain H5N1 infections can cause severe illness.
The new vaccine is intended for chickens, not humans. Its primary objective is to strengthen protection against the targeted H5N1 strain and reduce the risk of outbreaks spreading through poultry populations.
However, vaccination will need to work alongside disease surveillance, farm-level biosecurity, early detection and established outbreak-control measures.
₹300-Crore Research Laboratory Announced in Bhopal
In another significant announcement, Chouhan announced a state-of-the-art animal disease research laboratory in Bhopal at an estimated investment of ₹300 crore.
The proposed facility is expected to strengthen India’s research capabilities in high-risk animal pathogens, vaccine development and disease surveillance.
The minister also highlighted the contribution of India’s animal healthcare research institutions in developing indigenous vaccines against diseases affecting livestock and poultry.
The initiative is expected to enhance the country’s capacity to respond to emerging animal diseases while reducing dependence on foreign technologies.
A Milestone for India’s Poultry Industry
India’s poultry industry supports millions of farmers, entrepreneurs and workers and plays an important role in the country’s food and nutritional security.
Frequent outbreaks of avian influenza have remained a major challenge, threatening farm incomes, poultry production and domestic as well as international trade.
The development of an indigenous H5N1 vaccine therefore represents more than a scientific achievement. It could become an important instrument in India’s long-term strategy to strengthen animal disease management, protect rural livelihoods and improve the resilience of its poultry industry.
The actual impact, however, will depend on the vaccine’s effective deployment, availability and integration with comprehensive disease-control programmes.










